Reuters logo
BRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target
April 27, 2017 / 12:03 PM / 5 months ago

BRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target

April 27 (Reuters) - Agios Pharmaceuticals Inc

* Agios and aurigene enter into exclusive license agreement for novel small molecules for cancer metabolism target

* Agios pharmaceuticals inc - aurigene will provide agios exclusive rights to its portfolio of novel small molecules for undisclosed target

* Agios pharmaceuticals inc - financial terms of agreement include a $3 million upfront payment

* Agios-Deal inclides potential future milestone payments of up to $17 million per licensed product if certain milestones are achieved by agios Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below